[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,132
  • Shares Outstanding, K 7,251
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,310 K
  • EBIT $ -31 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.71 +4.58%
on 04/24/26
4.66 -16.74%
on 04/16/26
+0.13 (+3.47%)
since 03/27/26
3-Month
3.60 +7.78%
on 02/24/26
5.16 -24.77%
on 01/28/26
-1.01 (-20.65%)
since 01/27/26
52-Week
3.60 +7.78%
on 02/24/26
52.70 -92.64%
on 04/28/25
-48.12 (-92.54%)
since 04/25/25

Most Recent Stories

More News
BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line models Immune cells activated by Bria-OTS+ exhibit serial killing activity...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Fifth consecutive positive DSMB...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT...

BCT.TO : 5.33 (+0.57%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1075 (+2.38%)
BCTXL : 0.9650 (+8.37%)
BCTX : 3.92 (+1.03%)

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 4.29
2nd Resistance Point 4.14
1st Resistance Point 4.01
Last Price 3.92
1st Support Level 3.73
2nd Support Level 3.58
3rd Support Level 3.45

See More

52-Week High 52.70
Fibonacci 61.8% 33.94
Fibonacci 50% 28.15
Fibonacci 38.2% 22.36
Last Price 3.92
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.